Comparative analysis of clinical treatment of HIV positive and HIV negative bladder cancer patients

Abstract Objective: To provide clinical reference for the prevention and treatment of HIV positive bladder cancer by comparing and analyzing the basic information, laboratory examination, treatment and follow-up of HIV positive and non-HIV infected bladder cancer patients. Methods: This study collected 57 bladder cancer patients with complete data who were admitted to Beijing Ditan Hospital and Beijing You 'an Hospital from 2013 to 2021, including 14 cases in the HIV positive group and 43 cases in the HIV negative group. A retrospective analysis was conducted on the HIV infection route of HIV positive patients and whether antiviral treatment was regular. The viral load and the number of CD4+T lymphocytes before surgery were compared. The preoperative laboratory examination, pathological grade, treatment methods, 3-month recurrence and long-term follow-up of bladder cancer patients in the two groups were compared. Results: In this study, the average age of onset in the HIV positive group was (48.93±13.83) years old, while the average age of onset in the non-HIV group was (62.05±13.38) years old, and the difference was statistically significant (P<0.01). There were no statistically significant differences in the values of white blood cells, platelets, creatinine and albumin in preoperative laboratory tests between HIV group and non-HIV group (P>0.05), but there were statistically significant differences in red blood cell values between the two groups (P<0.05).There was no difference in pathological grade of bladder cancer between the two groups. The recurrence rate was 21.43% in HIV-positive patients and 23.26% in non-HIV patients at 3 months after surgery (P>0.05). The median long-term follow-up was 40 months (8-78 months). The survival rate of the two groups was HIV VS non-HIV (71.42% VS 93.02%) (P>0.05). Conclusions: The clinical characteristics of HIV-positive bladder cancer patients are similar to that of the general population, and HIV positive bladder cancer patients also follow the guidelines for the general population in terms of treatment measures. The early age of HIV positive bladder cancer patients remains to be further studied.